Sentences with phrase «androgen deprivation therapy in»

LIVE BROADCAST 5/11 2 PM EDT - Androgen Deprivation Therapy in Prostate Cancer and Cardiovascular Risk

Not exact matches

The authors focused on men newly diagnosed with localized (non-metastatic) prostate cancer in 1995 - 2011 and treated with radical prostatectomy, brachytherapy, radiation therapy, or primary androgen deprivation therapy (PADT).

Brachytherapy is an extremely efficient and safe radiation oncology modality, and this trial shows that it can have a wider field of applicability than simply in very localised and low risk tumours when combined with other techniques — in this case, androgen deprivation therapy and external bean radiation therapy.»

«There has been a groundswell of interest in the idea of reversing resistance to androgen deprivation therapy.

Preliminary results of a study of patients with prostate cancer show that MR tractography may be a reliable quantitative imaging biomarker to assess prostate cancer treatment response to androgen deprivation and radiation therapy, according to a team of researchers at Brigham and Women's Hospital and Massachusetts General Hospital in Boston.

The research teams, led by Nima Sharifi, M.D., of the Cleveland Clinic Lerner Research Institute, studied the role of the HSD3B1 (1245C) genetic variant in two different prostate cancer patient populations, following androgen deprivation therapy (ADT).

«Androgen deprivation therapy may lead to cognitive impairment in prostate cancer patients.»

«The risk of cognitive impairment should be considered when deciding whether or not to receive androgen deprivation therapy for prostate cancer,» said Brian Gonzalez, Ph.D., a postdoctoral fellow in the Health Outcomes and Behavior Program at Moffitt.

In current practice, men newly diagnosed with prostate cancer that has spread widely, and whose cancer depends on male hormones to grow, are started on hormone - blocking medications — androgen deprivation therapy (ADT).

Long - term follow - up of a large phase III study showed that chemohormonal therapy involving docetaxel added to androgen deprivation therapy (ADT) prolongs overall survival (OS) over ADT alone in metastatic hormone - sensitive prostate cancer (mHSPC) patients with high - volume disease.

Treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen - deprivation therapy.

A second phase 3 study presented Sunday found that adding radiation to hormone therapy, also known as androgen - deprivation therapy (ADT) in patients with locally advanced or high - risk prostate cancer reduced the seven - year risk of dying by 43 percent compared to treating with hormone therapy alone.

Common conventional treatment is androgen deprivation therapy (ADT), which drastically reduces testosterone levels resulting in many distressing side effects, such as sexual dysfunction.

With intermittent androgen deprivation, hormone therapy is given in cycles, with breaks between drug administrations, rather than continuously.